Skip to main content

Sullivan Timothy Eugene's Form 4 filing

Apellis Pharmaceuticals, Inc. (APLS) · filed Jun 6, 2023

Accession no.
0001127602-23-018065
Filed
Jun 6, 2023
Trade date
Jun 5, 2023
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.20M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Sullivan Timothy EugeneCIK 0001707000Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 5, 2023Common StockMOption exerciseAcquired+69,779$10.03+$699,883.37147,492Direct
Jun 5, 2023Common StockSSaleDisposed−1,600$90.60−$144,960145,892Direct
Jun 5, 2023Common StockSSaleDisposed−30,609$87.79−$2,687,164.11115,283Direct
Jun 5, 2023Common StockSSaleDisposed−7,064$88.36−$624,175.04108,219Direct
Jun 5, 2023Common StockSSaleDisposed−30,506$89.83−$2,740,353.9877,713Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 5, 2023Common StockMOption exerciseDisposed−69,779$0.00$0288,840Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)